CORESTEMCHEMON Inc.

KOSDAQ:A166480 Stock Report

Market Cap: ₩98.8b

CORESTEMCHEMON Balance Sheet Health

Financial Health criteria checks 0/6

CORESTEMCHEMON has a total shareholder equity of ₩24.1B and total debt of ₩40.0B, which brings its debt-to-equity ratio to 165.6%. Its total assets and total liabilities are ₩103.3B and ₩79.1B respectively.

Key information

165.6%

Debt to equity ratio

₩39.97b

Debt

Interest coverage ration/a
Cash₩2.50b
Equity₩24.14b
Total liabilities₩79.14b
Total assets₩103.28b

Recent financial health updates

Is CORESTEMCHEMON (KOSDAQ:166480) A Risky Investment?

Nov 01
Is CORESTEMCHEMON (KOSDAQ:166480) A Risky Investment?

Would CORESTEMCHEMON (KOSDAQ:166480) Be Better Off With Less Debt?

Aug 03
Would CORESTEMCHEMON (KOSDAQ:166480) Be Better Off With Less Debt?

Does CORESTEM (KOSDAQ:166480) Have A Healthy Balance Sheet?

Apr 12
Does CORESTEM (KOSDAQ:166480) Have A Healthy Balance Sheet?

Corestem (KOSDAQ:166480) Has Debt But No Earnings; Should You Worry?

Dec 25
Corestem (KOSDAQ:166480) Has Debt But No Earnings; Should You Worry?

Recent updates

CORESTEMCHEMON Inc.'s (KOSDAQ:166480) Popularity With Investors Under Threat As Stock Sinks 25%

Dec 09
CORESTEMCHEMON Inc.'s (KOSDAQ:166480) Popularity With Investors Under Threat As Stock Sinks 25%

Is CORESTEMCHEMON (KOSDAQ:166480) A Risky Investment?

Nov 01
Is CORESTEMCHEMON (KOSDAQ:166480) A Risky Investment?

CORESTEMCHEMON Inc.'s (KOSDAQ:166480) 27% Price Boost Is Out Of Tune With Revenues

Sep 24
CORESTEMCHEMON Inc.'s (KOSDAQ:166480) 27% Price Boost Is Out Of Tune With Revenues

Would CORESTEMCHEMON (KOSDAQ:166480) Be Better Off With Less Debt?

Aug 03
Would CORESTEMCHEMON (KOSDAQ:166480) Be Better Off With Less Debt?

What CORESTEMCHEMON Inc.'s (KOSDAQ:166480) 26% Share Price Gain Is Not Telling You

Jun 08
What CORESTEMCHEMON Inc.'s (KOSDAQ:166480) 26% Share Price Gain Is Not Telling You

CORESTEMCHEMON Inc.'s (KOSDAQ:166480) Shares Bounce 25% But Its Business Still Trails The Industry

Mar 05
CORESTEMCHEMON Inc.'s (KOSDAQ:166480) Shares Bounce 25% But Its Business Still Trails The Industry

Does CORESTEM (KOSDAQ:166480) Have A Healthy Balance Sheet?

Apr 12
Does CORESTEM (KOSDAQ:166480) Have A Healthy Balance Sheet?

If You Had Bought CORESTEM (KOSDAQ:166480) Shares A Year Ago You'd Have Earned 59% Returns

Feb 16
If You Had Bought CORESTEM (KOSDAQ:166480) Shares A Year Ago You'd Have Earned 59% Returns

Corestem (KOSDAQ:166480) Has Debt But No Earnings; Should You Worry?

Dec 25
Corestem (KOSDAQ:166480) Has Debt But No Earnings; Should You Worry?

Financial Position Analysis

Short Term Liabilities: A166480's short term assets (₩18.6B) do not cover its short term liabilities (₩52.6B).

Long Term Liabilities: A166480's short term assets (₩18.6B) do not cover its long term liabilities (₩26.6B).

Debt to Equity History and Analysis

Debt Level: A166480's net debt to equity ratio (155.2%) is considered high.

Reducing Debt: A166480's debt to equity ratio has increased from 0% to 165.6% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: A166480 has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: A166480 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 36.2% each year

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/07 05:26
End of Day Share Price 2025/01/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

CORESTEMCHEMON Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Byung Hwa HanEugene Investment & Securities Co Ltd.
Jiyong LeeShinhan Investment Corp.
Choongwoo SeoSK Securities Co., Ltd.